Qiongfeng XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
Type:
Grant
Filed:
January 28, 2015
Date of Patent:
November 14, 2017
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Xiao Ding, Qian Liu, Kai Long, Yingxia Sang, Luigi Piero Stasi, Zehong Wan, Qiongfeng Xu, Colin Michael Edge
Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
Type:
Application
Filed:
January 28, 2015
Publication date:
January 26, 2017
Inventors:
Xiao DING, Qian LIU, Kai LONG, Yingxia SANG, Luigi Piero STASI, Zehong WAN, Qiongfeng XU, Colin Michael EDGE
© 2025 Justia
